



Designation: F3208 – 17

## Standard Guide for Selecting Test Soils for Validation of Cleaning Methods for Reusable Medical Devices<sup>1</sup>

This standard is issued under the fixed designation F3208; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon ( $\epsilon$ ) indicates an editorial change since the last revision or reapproval.

### 1. Scope

1.1 This guide describes methods for selecting test soils for cleaning validations based upon the characteristics of the soil, the physical characteristics of the device, and the clinical use of the device.

1.2 This guide describes the preparation and use of some test soils for the validation of cleaning instructions for reusable medical devices.

1.3 Reusable medical devices such as endoscopes, arthroscopic shavers, surgical instruments, and suction tubes are exposed to biological soils during clinical use. Preparation of these devices for reuse requires cleaning and disinfection and/or sterilization as applicable. Adequate cleaning is the first step in a process intended to prevent contaminant transfer to the next patient and medical practitioner. The soils, if inadequately removed, can interfere with disinfection and sterilization processes, as well as performance of the device. Acceptance criteria are based either on a visual assessment or quantitatively specified marker(s) endpoint(s) of the soil or both (ISO/TS 15883-5, Section 1). Endpoints after cleaning should be based upon possible interference with disinfection/sterilization, risk to the patient or health care worker from the contaminant during further handling, and endpoints for cleaning established in the scientific literature.

1.4 The test soils are designed to simulate the contaminants that medical devices are likely to come in contact with during clinical use. The test soils discussed in this guide are a mixture of constituents that simulate what is commonly found in human secretions, blood, tissue, and bone fragments/shavings as well as non-patient derived soil (e.g., bone cement, lubricants, and dyes) during clinical procedures. The test soils also simulate the physical parameters (e.g., viscosity, adhesion) of clinical material to which the medical devices will be exposed.

#### 1.5 Exclusion:

1.5.1 This guide does not include methods to validate cleaning processes to remove residues from manufacturing

1.5.2 This guide does not describe the soil/inoculum used for validation of disinfection or sterilization instructions. Disinfection or sterilization validation requires separate testing that is independent of cleaning validation studies.

1.5.3 Test soils described are not intended for use by health care facilities to verify the effectiveness of their cleaning process.

1.5.4 The test soil recipes are not intended to encompass every biological residue with which a medical device is likely to come into contact.

1.6 Test soil formulations not described in this guide may be clinically relevant and may be more appropriate for simulated-use testing depending upon the clinical use of the medical device. The burden is upon the medical device manufacturer to determine and justify scientifically the selection of test soil(s).

1.7 The values stated in SI units are to be regarded as the standard. No other units of measurement are included in this standard.

1.8 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.*

### 2. Referenced Documents

#### 2.1 ASTM Standards:<sup>2</sup>

- D445 Test Method for Kinematic Viscosity of Transparent and Opaque Liquids (and Calculation of Dynamic Viscosity)
- D1193 Specification for Reagent Water
- D3330/D3330M Test Method for Peel Adhesion of Pressure-Sensitive Tape
- D3359 Test Methods for Measuring Adhesion by Tape Test
- D4212 Test Method for Viscosity by Dip-Type Viscosity Cups
- D4287 Test Method for High-Shear Viscosity Using a Cone/Plate Viscometer

<sup>1</sup> This test method is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.15 on Material Test Methods.

Current edition approved Jan. 15, 2017. Published March 2017. DOI: 10.1520/F3208-17.

<sup>2</sup> For referenced ASTM standards, visit the ASTM website, [www.astm.org](http://www.astm.org), or contact ASTM Customer Service at [service@astm.org](mailto:service@astm.org). For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

D7042 Test Method for Dynamic Viscosity and Density of Liquids by Stabinger Viscometer (and the Calculation of Kinematic Viscosity)

D7225 Guide for Blood Cleaning Efficiency of Detergents and Washer-Disinfectors

D7867 Test Methods for Measurement of the Rotational Viscosity of Paints, Inks and Related Liquid Materials as a Function of Temperature

F2809 Terminology Relating to Medical and Surgical Materials and Devices

2.2 *AAMI Standards*:<sup>3</sup>

TIR12:2010 Designing, testing, and labeling reusable medical devices for reprocessing in health care facilities: A guide for medical device manufacturers

TIR30:2011 A compendium of processes, materials, test methods, and acceptance criteria for cleaning reusable medical devices

2.3 *ISO Standard*:<sup>4</sup>

ISO/TS 15883-5 Washer-disinfectors—Part 5: Test soils and methods for demonstrating cleaning efficacy

2.4 *FDA Standard*:<sup>5</sup>

Reprocessing Medical Devices in Health Care Settings Validation Methods and Labeling—Guidance for Industry and Food and Drug Administration Staff

### 3. Terminology

3.1 *Definitions*—Unless provided otherwise in the following definitions, terminology shall be in conformance with Terminology F2809.

3.1.1 *cleaning, n*—removal of contamination from a medical device to the extent necessary for further processing or for intended use.

3.1.2 *cleaning marker, n*—that which is being detected/measured to determine soil removal/retention.

3.1.3 *contamination, n*—procedure of applying simulated test soil onto a medical device for determination of process capability (that is, cleaning efficacy and extraction yields).

3.1.4 *test soil, n*—single substance or a mixture of substances that reflect the contaminants likely to be encountered during the use of the device in its intended clinical procedure.

3.1.5 *validation, n*—documented procedure for obtaining, recording, and interpreting the results required to establish that a process will consistently yield results complying with predetermined specifications.

3.1.5.1 *Discussion*—Under U.S. FDA guidelines, validation of the instructions for cleaning is the responsibility of the medical device manufacturer.

<sup>3</sup> Available from Association for the Advancement of Medical Instrumentation (AAMI), 4301 N. Fairfax Dr., Suite 301, Arlington, VA 22203-1633, <http://www.aami.org>.

<sup>4</sup> Available from International Organization for Standardization (ISO), ISO Central Secretariat, BIBC II, Chemin de Blandonnet 8, CP 401, 1214 Vernier, Geneva, Switzerland, <http://www.iso.org>.

<sup>5</sup> Available from U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave., Silver Spring, MD 20993, <http://www.fda.gov>.

### 4. Summary of Guide

4.1 This guide provides information on the selection of test soil formulation(s) based upon clinical use and physical characteristics of clinically occurring soiling of the device.

4.2 This guide provides the sample preparation technique for some test soils that simulate the soils found on medical devices as a result of clinical use.

4.3 An important aspect of the cleaning validation is determining the appropriate test soil(s) used to contaminate the device.

4.3.1 The manufacturer of the medical device or the reprocessing equipment shall justify why the specific soil(s) was chosen and is appropriate for all cleaning markers/assays to be measured.

4.3.2 The determination and selection of soil(s) shall be based upon the intended clinical use of the medical device. The manufacturer needs to determine what the device will come in contact with (e.g., blood, mucus, cerebrospinal fluid, neurological tissue, etc.) during clinical procedures how (e.g., duration, complete immersion).

4.3.3 The manufacturer should select a test soil(s) composed of a formulation that includes or accurately represents materials that the device would likely be subjected to during clinical use and would create the worst-case challenge to the cleaning process

4.3.4 Ideally, the formulation of the test soil should be composed of well-defined chemical/biochemical ingredients and readily reproduced by any laboratory globally.

### 5. Significance and Use

5.1 This guide provides information on how to select the test soil(s) that best simulates clinical use for devices. The test soil(s) selected for the validation should be clinically relevant and simulate what the device/component will come into contact with during the clinical procedure.

5.2 This guide will help standardize the test soils used by medical device manufacturers when validating the cleaning procedures of reusable medical devices and reprocessing equipment

5.3 For devices that come into contact with blood, the simulated test soils are blood-based soils, such as those described under 7.1.1 – 7.1.5.

5.4 For devices that come into contact with mucus, the simulated test soils are those described under 7.1.6.

5.5 For devices that come in contact with soils of a source other than the patient (e.g., bone cement), the simulated test soils should be similar to those described in 7.2. These can be used alone or in combination with 7.1.

5.6 A combination of test soils may be used (e.g., blood with mucus) to simulate clinical soiling. For example, flexible endoscopes may come in contact with a different combination of sources of soiling (e.g., gastrointestinal (GI) tract, vasculature for biopsies) during clinical use.

5.7 Any simulated test soil(s) or formulations can be used for simulated use testing but shall be scientifically justified by the medical device manufacturer.

## 6. Soil Selection Criteria

6.1 The test soils mentioned in this guide may be used to validate cleaning procedures as long as they can be scientifically justified as simulating clinical soiling.

6.2 Other formulations or modifications to the test soil(s) can be made but shall be scientifically justified by the manufacturer as simulating clinical soiling.

6.3 Mixtures of different soils can be made depending on how the device would be contaminated during a clinical procedure.

6.3.1 When selecting a combination of soils, consideration shall be given to the clinical use of the device and the ratio of the soil(s) in the combined test soil that best simulates clinically occurring soiling reflecting worst-case conditions.

6.4 Contamination by blood during clinical use is a common occurrence. There are multiple choices in the kind of blood soil selected for use.

6.4.1 In clinical procedures in which the predominant soil is blood, and other agents (e.g., water for irrigation) that will not interfere with the coagulation cascade, blood that can be chemically induced to coagulate is used. The coagulation process is induced before soiling the device.

6.4.2 In clinical procedures in which blood is not the predominant soil or other agents are present in sufficient volume to prevent coagulation, defibrinated blood is used.

NOTE 1—If whole blood is extracted without defibrination or without adding an anticoagulant, it forms clots and clumps. As a result, it is not easily used in test soil formulations.

### 6.4.3 Types of Blood

6.4.3.1 *Defibrinated Blood*—Whole blood that has been treated to denature fibrinogen without causing cell lysis.

6.4.3.2 *Anticoagulated Whole Blood*—Anticoagulated whole blood is selected in instances in which coagulation is to be induced at the time of application to the device.

(1) *Citrated Blood*—Blood treated with sodium citrate to prevent coagulation. Coagulation is induced with calcium chloride.

(2) *Heparinized Blood*—Blood rendered incoagulable by addition of heparin. Coagulation is induced with protamine sulfate.

## 7. Test Soils

7.1 *Test Soils Formulated to Simulate Patient-Derived Soils*—During clinical use, the key contaminants a medical device comes in contact with are from the patient. The soils described in this section are formulations that are intended to simulate the characteristics of these soils as they represent a challenge to cleaning.

7.1.1 *Coagulating Blood-Based Soils*—Blood is often the only or predominant patient derived soil that medical devices come into contact with during clinical use. When this is the case, the blood is likely to coagulate prior to the initiation of cleaning steps, particularly in a worst-case scenario. Coagulated blood proteins are highly water insoluble and can significantly adhere to the medical device. The test soils in this section are intended to simulate the characteristics of coagulating blood.

### 7.1.2 Two Component Blood Test Soil

7.1.2.1 *Description*—A test soil correlating to coagulated blood is based on a proteinaceous matrix containing fibrinogen and thrombin in two separated components. Coagulation of the soil is induced after mixing these two components. Guide **D7225** and Pfeifer **(1)**<sup>6</sup> describe this soil in further detail.

7.1.2.2 *Constituents*—The blood test soil includes the following:

#### (1) Component A

Albumin, bovine, protease free: 400 mg;

Hemoglobin, bovine, lyophilized: 400 mg;

Fibrinogen, bovine, lyophilized: 60 mg; and

Solvent A, 5.0 mL 0.4 % NaCl solution (reagent grade NaCl dissolved in sterile water).

#### (2) Component B

Albumin, bovine, protease free: 400 mg;

Hemoglobin, bovine, lyophilized: 400 mg;

Thrombin, reagent grade from bovine plasma: 12.5 NIH units; and

Solvent B, 5.0 mL 0.4 % NaCl solution (reagent grade NaCl dissolved in sterile water) + 8.0 mmol/L CaCl<sub>2</sub>.

### 7.1.2.3 Preparation

(1) The soil is prepared by separately dissolving Components A and B in their respective solvents by shaking for 1 h at room temperature.

(2) Immediately before use, Components A and B are mixed together in a 1:1 ratio.

7.1.2.4 *Markers*—Suggested (not exclusive) cleaning markers for residual analysis: protein, hemoglobin, and total organic carbon (TOC).

### 7.1.3 Blood Test Soil

7.1.3.1 *Constituents*—Components of test soil include the following:

(1) Whole sheep blood, citrated: 100 mL;

(2) Bovine calf serum 50 mL;

(3) Physiological saline solution (PHSS): 50 mL, 0.9 % NaCl; and

(4) 0.01 mL of 2M CaCl<sub>2</sub>.

7.1.3.2 *Preparation*—The soil is prepared by mixing all the whole blood with blood serum and the saline solution together thoroughly. Then add the 0.01 mL of 2M CaCl<sub>2</sub> calcium chloride immediately before use to activate the coagulation.

NOTE 2—Because of different composition of citrated sheep's blood commercially available, it may be necessary to adjust the amount of calcium chloride used to ensure adequate coagulation.

7.1.3.3 *Markers*—Suggested (not exclusive) cleaning markers for residual analysis: protein, TOC, hemoglobin, and carbohydrates.

7.1.4 *Non-Coagulating Blood-Based Soils*—Depending upon the area of the body, or the nature of the clinical procedure, blood may be present, but coagulation of the blood does not occur. For example, while blood may be present for procedures in the GI tract, other contaminants are also found in such significant proportions as to inhibit the coagulation of blood. In other procedures, such as many laparoscopic

<sup>6</sup> The boldface numbers in parentheses refer to a list of references at the end of this standard.

procedures, copious water flushing is used during the procedure, thus inhibiting the coagulation of the blood. The soils described in this section are meant to simulate clinical contaminants of this kind.

#### 7.1.4.1 Artificial Test Soil (ATS) (2)

##### (1) Constituents

Rosewell Park Memorial Institute (RPMI) 1640: 10.4 g;

Heat inactivated Bovine Calf Serum: 100 mL;

(optional) Bovine Oxgall: 20 g;

Sterile defibrinated sheep blood: 20 % by total volume of final solution;

Sodium bicarbonate: 2 g;

100 mM sodium pyruvate: 10 mL;

L-Glutamine: 10 mL of 200 mM; and

Total volume 1 L with distilled water.

(2) Preparation—Add Add the Bovine Oxgall, RPMI and sodium bicarbonate to a beaker. Add 700 ml of distilled water and mix well. Then add sodium pyruvate and L-glutamine and again mix well. Pour this mixture into a graduated cylinder. Add distilled water as needed to reach a total volume in the graduated cylinder of 1 L. Filter the entire volume through a 0.22 µL membrane filter into a sterile bottle. Using sterile technique add the sterile sheep blood and calf serum and mix well.

(3) The test soil may also be purchased in a lyophilized state.

(4) Markers—Suggested (not exclusive) cleaning markers for residual analysis: protein, TOC, hemoglobin, lipids and carbohydrates.

#### 7.1.4.2 Blood Test Soil (BTS)

##### (1) Constituents

Bovine albumin: 0.5 g;

Bovine hemoglobin: 1.0 g;

Sodium alginate: 8.3 mg;

27 mL of sterile water for irrigation; and

Calcium chloride solution: 15 mM CaCl<sub>2</sub>.

(2) Preparation—Mix the albumin, hemoglobin and sodium alginate in a sterile container. Add the 27 mL of sterile water for irrigation and calcium chloride and vortex to homogenize the soil. Sodium alginate and calcium chloride cross link to form alginate hydrogels. These three-dimensional (3-D) protein hydrogels simulate the fibrin hydrogels in clotted blood.

(3) The blood test soil may also be purchased in a lyophilized state.

(4) Markers—Suggested (not exclusive) cleaning markers for residual analysis: protein, TOC, and hemoglobin.

#### 7.1.4.3 Defibrinated Blood Soil

(1) Constituents—The test soil shall have the following composition:

Fresh egg yolk: 100 mL;

Defibrinated blood: 100 mL sheep blood; and

Dehydrated hog mucin: 2g.

(2) Preparation—Mix all the ingredients together thoroughly in a blender until a liquid uniform mixture is achieved.

(3) Markers—Suggested (not exclusive) cleaning markers for residual analysis: protein, TOC, hemoglobin, and carbohydrates.

#### 7.1.4.4 Simulated Ophthalmic Test Soil (3)

(1) Constituents—The test soil shall have the following composition:

Dried egg yolk: 0.8 g;

Defibrinated blood: 10 mL (horse or sheep); and

Dehydrated hog mucin: 01 g.

(2) Preparation—Mix the components to give a liquid of uniform consistency.

(3) Markers—Suggested (not exclusive) cleaning markers for residual analysis: protein, TOC, hemoglobin, and carbohydrates.

NOTE 3—This test soil is not recommended to evaluate the cleaning of contact lenses.

#### 7.1.5 Simulated Mucus Test Soils

##### 7.1.5.1 British Standard Soil

(1) Constituents—The test soil shall have the following composition:

Bovine serum: 10 mL;

Dry milk powder: 6 g; and

Saline (PHSS): 10 mL.

(2) Preparation—Mix all the ingredients together thoroughly in an appropriate container using a hot plate (temperature between 30 and 35°C) and a magnetic stirrer until a liquid uniform mixture is achieved. Heat to dissolve; do not boil.

(3) Markers—Suggested (not exclusive) cleaning markers for residual analysis: protein, TOC, hemoglobin, and carbohydrates.

##### 7.1.5.2 Miles Test Soil

(1) Constituents—The test soil shall have the following composition:

Fetal bovine serum: 10 mL;

Saline physiological saline solution (PHSS): 1 mL;

Dry milk powder: 6 g; and

Rabbit blood in citrate: 1 mL.

(2) Preparation—Mix the fetal bovine serum, saline, and dry milk powder together thoroughly using a hot plate (temperature between 30 and 35°C) and a magnetic stirrer until a uniform liquid mixture is achieved. When the soil cools down to 20-25°C, add the rabbit blood to the prepared soil and mix thoroughly.

(3) Markers—Suggested (not exclusive) cleaning markers for residual analysis: protein, TOC, hemoglobin, and carbohydrates.

##### 7.1.5.3 Artificial Mucus Soil (4)

(1) Description—The artificial mucus soil uses a modified artificial cystic fibrosis mucus formulation.

(2) Constituents—Components of test soil:

Mucin from pig mucosa: 1000 mg;

Casein hydrolysate: 500 mg;

NaCl: 500 mg;

Diethylene triamine pentaacetic acid (DTPA): 0.59 mg;

ASTM Water Type 1 (Specification **D1193**) water: 80 mL;

KCl: 500 mg;

Salmon sperm DNA: 140 mg;

Freeze dried egg yolk emulsion: 232 mg; and

Phosphate buffered saline (PBS) without Ca and Mg: 8.5 mL.



### (3) Preparation

Reconstitute the dried egg yolk in PBS without CaCl<sub>2</sub> or MgCl<sub>2</sub>.

Add mucin to 80 mL distilled and deionized water and put on a stir plate at ~380 rpm for 4-5 h or overnight.

While still stirring, add in remaining ingredients.

Remove from stirrer and add 20 mL distilled and deionized water.

Bring pH to 6.5-7 using NaOH or HCl.

(4) Markers—Suggested (not exclusive) cleaning markers for residual analysis: protein, TOC, and carbohydrates.

#### 7.1.6 *Fecal Matter Test Soil* (4)

7.1.6.1 *Constituents*—Components of test soil:

- (1) Cholesterol: 775 mg;
- (2) Bile acid: 585 mg;
- (3) Cotton seed oil: 1.81 mL;
- (4) Cellulose: 668 mg;
- (5) Distilled deionized water: 35 mL;
- (6) Lignin: 752 mg;
- (7) Galactose: 511 mg;
- (8) Casein hydrolysate: 1500 mg; and
- (9) Xylose: 511 mg.

#### 7.1.6.2 *Preparation*

(1) Mix all ingredients into the distilled, deionized water with constant stirring.

(2) Autoclave for 15 min at 121°C.

7.1.6.3 *Markers*—Suggested (not exclusive) cleaning markers for residual analysis: protein, TOC, and carbohydrates.

#### 7.1.7 *Simulated Skin Secretion Soil* (5)

7.1.7.1 *Description*—Natural sebum is secreted by the microscopic sebaceous glands in skin to lubricate and waterproof the skin and hair of mammals. Sebum is mixture of naturally produced fats, oils, waxes, cholesterol, and other molecules and is a key component of the skin surface. It also functions as a nutritional source by harboring certain skin microflora.

7.1.7.2 *Constituents*—Components of test soil: A9 synthetic sebum.

#### 7.1.7.3 *Preparation*:

(1) An aliquot of the sebum is diluted (1:1) in glycerol and incubated in a water bath at 40°C to keep it in solution.

(2) Bacteria may be suspended in the sebum-glycerol mixture and inoculated on the test surface.

7.1.7.4 *Markers*—Suggested (not exclusive) cleaning markers for residual analysis: lipids.

7.2 *Test Soils Formulated to Simulate Non-Patient Derived Soils*—For many medical devices, the primary contaminants are derived from the patient, whereas for some medical devices, there are also contaminants derived from non-patient sources that pose very significant challenges to cleaning. Examples include adhesives and bone cement.

7.2.1 *Simulated Test Soil for Surgical Tools Used During Ophthalmic Procedures* (6)

7.2.1.1 *Description*—During cataract surgery and other ophthalmic procedures, Ophthalmic Viscosurgical Devices (OVDs) are used to protect the corneal endothelium and provide mechanical support to the anterior chamber of the eye. Reusable ophthalmic surgical tools (e.g. reusable intraocular lenses (IOL) injectors) can be soiled with the OVD during

ophthalmic procedures. Due to the viscous nature of these substances it is challenging to remove them from the lumens and other difficult-to-reach areas of the reusable surgical tools. Thus, simulated OVDs are a worst-case test soil for these reusable devices. The simulated OVD soils are broadly classified as being either dispersive or cohesive.

OVDs are commonly classified into two viscosity categories:

(1) dispersive OVDs have a lower viscosity and the ability to coat intraocular structures;

(2) cohesive OVDs have a higher viscosity and are able to pressurize the eye and create space.

The commonly used OVDs are composed of the following materials:

- (1) sodium hyaluronate (NaHA);
- (2) chondroitin sulfate (CS); and
- (3) hydroxypropyl methylcellulose (HPMC).

7.2.1.2 Manufacturers of reusable ophthalmic devices should consider the type of OVD that their device is most likely to be soiled with in clinical use to determine the appropriate test soil formulation. Based on the prevalence of sodium hyaluronate in various OVDs, device manufacturers that seek to incorporate an OVD component in their test soil may choose a sodium hyaluronate-based OVD formulation, either alone or in combination with other OVD materials.

7.2.1.3 *Constituents*—The test soil will have the following composition:

(1) *Simulated Dispersive OVDs*—2 % (20mg/mL) hydroxypropylmethylcellulose (HPMC) with a molecular weight of approximately 80 000 Daltons and viscosity of approximately 4000 mPa·s. These are based on buffered phosphate solutions so, if adjustment of the viscosity is necessary, this may be accomplished with common phosphate buffers or purified water.

(2) *Simulated Cohesive OVDs*—1.6 % (16 mg/mL) sodium hyaluronate with a molecular weight of approximately 4 000 000 Daltons and a viscosity of approximately 300 000 mPa. These are based on buffered phosphate solutions so, if adjustment of the viscosity is necessary, this may be accomplished with common phosphate buffers or purified water.

NOTE 4—This may be mixed in a 1:1 ratio with defibrinated blood to add an organic challenge (6).

7.2.1.4 *Markers*—Suggested (not exclusive) cleaning markers for residual analysis: TOC. If defibrinated blood is added, additional markers include protein and hemoglobin.

#### 7.2.2 *Artificial Bone/Bone Cement Test Soil* (7)

7.2.2.1 *Constituents*:

- (1) Polyphosphoric acid,
- (2) B tricalcium phosphate,
- (3) Alizarin Red S,
- (4) Sucrose,
- (5) Distilled deionized water,
- (6) Hydroxyapatite bone cement,
- (7) 73.2 % tetracalcium phosphate, and
- (8) 26.8 % anhydrous dicalcium phosphate.

7.2.2.2 *Preparation*:

- (1) Mix 6 mL of citrate solution, 6 mL with bone powder;

(2) Stir with a polytetrafluorethylene spatula immediately for 30 s;

(3) After adding the last ingredient that initiates polymerization of the bone cement, mix well and use immediately; and

(4) Allow to dry on the substrate overnight at room temperature.

7.2.2.3 *Markers*—Suggested (not exclusive) cleaning markers for residual analysis: bone detection methods.

7.3 *Adding Microorganisms to Test*—Microorganisms may be added to the above test soils for use in cleaning validation studies. Microbial log reduction can then be measured as part of the cleaning efficacy tests. Historically, *Geobacillus stearothermophilus* spores were used for cleaning validations (AAMI TIR30). Although this organism is rarely found in clinical material and, therefore, is not representative of what devices are exposed to in clinical use. The U.S. Food and Drug Administration (FDA) does not recommend the use of microbial or spore log reduction testing as a method to determine the effectiveness of the cleaning methodology (unless a scientific justification can be made that when used clinically, the device will have clinical contact with contaminants containing significant amounts of microorganisms). However, other national/international regulatory agencies/bodies request data on microbial log reduction along with the organic markers for cleaning. Therefore, seeking advice from the relevant regulatory bodies regarding microbial log reduction testing before undertaking cleaning validation testing is strongly recommended.

## 8. Validating the Shelf Life of Test Soil

8.1 Test soils should be mixed and used immediately unless validated testing has demonstrated that the soil can be kept in storage for a defined period of time.

8.2 The criteria for determining if a soil can be kept in storage include:

8.2.1 The key marker(s) for detecting residual soil (e.g., protein) is validated as being within the specified (clinically relevant) range at the beginning and at the end of the storage period.

8.2.2 The physical characteristics (see Section 9) of the test soil are validated as being within the specified (clinically relevant) range at the beginning and end of the storage period.

8.2.3 The conditions of storage (e.g., refrigerated or room temperature) are stated and have been validated.

8.2.4 The positive control values for the marker(s) should confirm the stated values for test soil that was in storage.

8.2.5 The maximum length of time validated for storage is stated.

## 9. Physical Characterization of Test Soils

9.1 *General Discussion*—Test soils may be characterized based upon various physical properties. These properties can be used to compare one test soil to another. More importantly, these properties may be used to compare a test soil to the actual clinical contaminants (or contamination) found on a clinically used medical device. This may further help demonstrate the appropriate selection of a test soil for a given device. The methods described here can be used to help justify the selection

of test soils detailed in this guide as well as test soil formulations not described in this guide.

### 9.2 Component Composition

9.2.1 Section 7 describes the composition of each test soil.

9.2.2 The composition of a test soil is meant to simulate the composition of contamination that occurs during clinical use of the device.

### 9.3 Viscosity

9.3.1 *General Discussion*—Viscosity is a measure of a fluid's resistance to flow. It is one of the most important properties of a fluid. The viscosity of a liquid will influence how it flows and ultimately contaminates a medical device.

#### 9.3.2 Selecting a Viscosity Test Method

9.3.2.1 There are a number of ways to measure viscosity and these are described in Test Methods [D445](#), [D7867](#), and [D4287](#).

9.3.2.2 One significant consideration, particularly when assessing clinically occurring soils, is the volume of soil required to conduct a given viscosity test method ([8](#), [9](#)). A couple of viscometers that are suited to using relatively low volumes are plate and cone viscometers and vibrational viscometers.

### 9.4 Adhesion

9.4.1 Another important physical characteristic of a soil is its adhesive properties. The stronger a soil adheres when it dries on a surface, the more difficult it is likely to be to remove during cleaning.

9.4.2 Key factors in adhesion are the composition of the soil itself and also the composition of the surface of the medical device. Adhesion of test soil will depend upon the type of device material (for instance, stainless steel, plastic, silicone, and so forth), the condition of the surface (for instance, smooth, bumpy, scratched, and so forth), and the mechanism of adhesion (for instance, chemical bonds or intermolecular forces).

#### 9.4.3 Methods for Testing Adhesion

9.4.3.1 Test Methods [D3359](#) describe a method for evaluating the adhesion of a coating dried onto the substrate by applying and then removing adhesive tape. The amount of soil removed by the adhesive tape provides a measure of the adhesion of the test soil. This method can be used to evaluate and compare the adhesive characteristics of test soils and clinically occurring test soils to a variety of substrates ([8](#), [9](#)).

9.4.3.2 Test Method [D3330/D3330M](#), Test Method F, describes a method for evaluating the adhesion of pressure-sensitive adhesive tape to a surface using a pull-tester. Following this method for conducting the pull test provides a means to reduce variability between test runs by use of a mechanical pull-tester ([9](#)).

### 9.5 Solubility

9.5.1 Water alone or water with a cleaning agent (e.g., a detergent) are the most common fluids used in the cleaning of medical devices in a health care facility. A key characteristic of a test soil dried on a surface is how readily it dissolves in water alone without use of a chemical additive or mechanical action. Clinical soils are comprised of water-soluble and water-insoluble components. Further, factors such as drying time and temperature affect how clinical soils adhere and how their

formulation may be adjusted to provide a greater challenge to cleaning (see 8.2.3). Characterizing how dried test soils and clinical soils are solubilized in water may be useful.

9.5.2 Guide **D7225** describes a method for testing a soiled coupon in static fluid. This method may be used to test with water alone (9).

9.5.2.1 If using water alone and the test soil includes proteins, use a water temperature below 45°C to avoid denaturing the proteins (AAMI TIR12, Section 4.2.4.2).

#### 9.6 Testing Soil Adhesion inside a Lumen

9.6.1 Soils may behave differently when inside a lumen than when on the external surface of a medical device. Drying of the test soil inside of a lumen likely will take much longer than drying on a device surface. (This will depend on the internal diameter and length of the lumen.) To characterize soil removal from within a lumen, an alternate method to static water exposure is needed.

9.6.1.1 *Assessing Soil Removal by Measuring Cleaning Marker(s)* (10)

(1) Completely perfuse the lumen with test soil and flush the channel with air to remove excess soil.

(2) Allow the inoculated lumen to dry.

(3) Flush with water to extract a test sample from the lumen to quantitate the level of residual organic material. The test sample is collected by flushing the lumen with a prescribed amount of extraction solution (e.g, deionized water). Two to three times the volume of the channel is appropriate to provide adequate extraction.

(4) Calculate the amount of soil removed by water by measuring the marker(s) (e.g., protein, hemoglobin, carbohydrate) in the recovered water to assess the relative amount of soil removed by water only.

9.6.1.2 *Assessing Soil Removal by Gravimetric Measurement* (9)

#### (1) Cutting and pre-cleaning the tubing

Cut the tubing to a determined length. The volume of the lumen shall be calculated to determine the amount of soil and water needed during the testing.

Flush the tube's lumen and brush with an appropriate sized brush and then flush again to remove any "loose" debris that may have be inside.

Let the tube air-dry overnight and weigh the following day.

#### (2) Soiling the lumen

Pipette soil equal to the lumen volume, allowing the lumen to be completely perfused.

Ensure that the soil comes in contact with the entire inside of the lumen.

Drain out excess fluid.

Lay the tubing flat on a surface to allow overnight drying of the soil.

Weigh the tube again the following day.

#### (3) Flushing with water and air

Flush three times the volume of the lumen with sterile water.

Inject the lumen with a steady flow of instrument grade air for a set amount of time.

Lay the tube flat on a surface and allow to dry overnight.

After drying overnight weigh the lumen again to determine the removal of soil.

## 10. Keywords

10.1 bone test soil; cleaning; cleaning efficacy; cleaning validation; coagulating blood test soil; extraction efficiency; medical device; non-coagulating blood test soil; non-patient sourced test soil; ophthalmic test soil; patient derived soil; test soil; testing efficacy

## REFERENCES

- (1) Pfeifer, M., "Blood as a soil on surgical Instruments: Chemical profile, cleaning, detection," *Zentr Steril*, 1997, Vol 6, 381-385.
- (2) Alfa, M. J., DeGagne, P., and Olson, N., "Validation of ATS as an Appropriate Test Soil," *Zentr Steril*, Vol 13, No. 6, 2005, pp. 387-402.
- (3) McCormick, P. J., Kaiser, J. J., Schoene, M. J., Shlutz, D. L., and Norton, S. E., "A Designed Experiment for Evaluation of the OPA Method for Cleaning Studies of Medical Devices," *Biomedical Instrumentation & Technology*, Vol 41, No. 4, July 2007, pp. 324-331.
- (4) Kelly, K. E., Gonzalez, E. A., Hitchins, V. M., and Lucas, A. D., "Chemically defined, clinically relevant test soils for cleaning validation of reusable medical devices," *Central Service*, 2015, Vol 23, 6, 418-423.
- (5) Nandy, P., Lucas, A. D., Gonzalez, E. A., and Hitchins, V. M., "Efficacy of commercially available wipes for disinfection of pulse oximeter sensors," *AJIC Online*, November 2015.
- (6) McCormick, P. J., Kaiser, J. J., Schoene, M. J., Dehmler, M. A., conyer, J. M., et al, "Ophthalmic Viscoelastic Devices as a Cleaning Challenge," *BI&T*, Vol 47, 4, July/August 2013.
- (7) Lucas, A. D., Nagaraja, S., Gordon, E. A., and Hichins, V. "Evaluating Device Design and Cleanability of Orthopedic Device Models Contaminated with a Clinically Relevant Bone Test Soil," *BI&T*, September/October 2015, pp. 354-362.
- (8) Alfa, M. J., DeGagne, P., and Olson, N., "Physical and composition characteristics of clinical secretions compared with test soils used for validation of flexible endoscope cleaning," *Journal of Hospital Infection*, Vol 93, Issue 1, May 2016, pp. 83-88.
- (9) Basile, R., Patel, A., and Kulkarni, K., "Characterization Simulated-Use Test Soils Used in Reprocessing Validations," *BI&T*, Vol 50, Issue 3, April 2016, pp. 11-18.
- (10) Alfa, M. J., DeGagne, P., and Olson, N., "Worst-case soiling levels for patient-used flexible endoscopes before and after cleaning," *Am J Infect Control*, Vol 27, No. 5, October 1999, pp. 392-401.

*ASTM International takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.*

*This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years and if not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standards and should be addressed to ASTM International Headquarters. Your comments will receive careful consideration at a meeting of the responsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you should make your views known to the ASTM Committee on Standards, at the address shown below.*

*This standard is copyrighted by ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the above address or at 610-832-9585 (phone), 610-832-9555 (fax), or [service@astm.org](mailto:service@astm.org) (e-mail); or through the ASTM website ([www.astm.org](http://www.astm.org)). Permission rights to photocopy the standard may also be secured from the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, Tel: (978) 646-2600; <http://www.copyright.com/>*